Characteristics and features of the formation of humoral immunity after immunization with Sputnik V and Vero Cell vaccines

The presented work contains an analysis of seroprevalence, tension, and duration of post-vaccination immunity to the SARS-CoV-2 coronavirus in the residents of the Republic of Belarus after immunization with two vaccine preparations available in the country: Sputnik V and Vero Cell.

It was found that seroconversion after the injection of the Vero Cell vaccine occurred significantly later than after the Sputnik V vaccine (p < 0.001). Nevertheless, two-stage immunization with the vaccines provided a sufficiently high efficiency of the inoculated antibodies to the S protein of the COVID-19 pathogen: the proportion of seropositive persons reached 99.19 [96.89; 99.97] % for Sputnik V and 96.03 [90.81; 98.53] % for Vero Cell. The efficiency of antibody formation after immunization with the Vero Cell vaccine was lower in older persons (in the group > 65 years). The proportion of individuals with the highest IgG score for the SARS-CoV-2 S protein was higher after the Sputnik V administration compared to that in response to the Vero Cell vaccine (p < 0.05), and gradually decreased over time. However, no significant decrease in the level of seropositive individuals after 90 days from the start of immunization with the both vaccine preparations was detected. In COVID-19 survivors immunized with the Sputnik V vaccine, the quantitative indicators of post-vaccination antibodies reached their peak values after 1 dose of the vaccine. The obtained results complement the accumulated world science and practical information on the problem of the postvaccination immunity formation in the context of the use of different drugs against COVID-19.>< 0.001). Nevertheless, two-stage immunization with the vaccines provided a sufficiently high efficiency of the inoculated antibodies to the S protein of the COVID-19 pathogen: the proportion of seropositive persons reached 99.19 [96.89; 99.97] % for Sputnik V and 96.03 [90.81; 98.53] % for Vero Cell. The efficiency of antibody formation after immunization with the Vero Cell vaccine was lower in older persons (in the group > 65 years). The proportion of individuals with the highest IgG score for the SARS-CoV-2 S protein was higher after the Sputnik V administration compared to that in response to the Vero Cell vaccine (p < 0.05), and gradually decreased over time. However, no significant decrease in the level of seropositive individuals after 90 days from the start of immunization with the both vaccine preparations was detected. In COVID-19 survivors immunized with the Sputnik V vaccine, the quantitative indicators of post-vaccination antibodies reached their peak values after 1 dose of the vaccine.

The obtained results complement the accumulated world science and practical information on the problem of the postvaccination immunity formation in the context of the use of different drugs against COVID-19.

1. Searching for a vaccine against COVID-19 [Electronic resource]. Available at: https://www.who.int/ru/emergencies/ diseases/novel-coronavirus-2019/covid-19-vaccines (accessed 20.06.2021) (in Russian).

2. Oliver S. E., Gargano J. W., Marin M., Wallace M., Curran K. G., Chamberland M. [et al.]. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States. MMWR. Morbidity and Mortality Weekly Report, 2020, vol. 69, no. 50, pp. 1922‒1924. https://doi.org/10.15585/mmwr.mm6950e2

3. Ledford H. Moderna COVID vaccine becomes second to get US authorization. Nature, 2020. https://doi.org/10.1038/ d41586-020-03593-7

4. Dagan N., Barda N., Kepten E., Miron O. Perchik Sh., Katz M. A. [et al.]. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine, 2021, vol. 384, no. 15, pp. 1412‒1423. https://doi. org/10.1056/NEJMoa2101765

5. Summary of the Public Assessment Report for COVID-19 Vaccine AstraZeneca. Available at: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/summary-of-the-public-assessment-report-forastrazeneca-covid-19-vaccine (accessed 19.07.2021).

6. Coronavirus (COVID-19) Vaccinations [Electronic source]. Available at: https://ourworldindata.org/covid-vaccinations (accessed 19.07.2021).

7. Logunov D. Y., Dolzhikova I. V., Shcheblyakov D. V., Tukhvatulin A. I., Zubkova O. V., Dzharullaeva A. S. [et al.]. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, vol. 397, no. 10275 pp. 671‒681. https://doi.org/10.1016/S0140- 6736(21)00234-8

8. Elslande J. V., Oyaert M., Ailliet S., Ranst M.V., Lorent N., Weygaerde Y. V., André E., Lagrou K., Vandendriessche S., Vermeersch P. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. Journal of Clinical Virology, 2021, vol. 136, p. 104765 https://doi.org/10.1016/j.jcv.2021.104765

9. Elslande J. V., Gruwier L., Godderis L., Vermeersch P. Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers. Clinical Infectious Diseases, 2021. https://doi.org/10.1093/cid/ciab219

10. Kopel J., Perisetti A., Roghani1 A., Aziz M., Gajendran M., Goyal H. Racial and gender-based differences in COVID-19. Frontiers in Public Health, 2020, vol. 6, art. 418. https://doi.org/10.3389/fpubh.2020.00418

11. Ebinger J. E., Fert-Bober J., Printsev I., Wu M., Sun N., Prostko J. C. [et al.]. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine, 2021, vol. 27, no. 6, pp. 981‒984. https://doi.org/10.1038/s41591-021-01325-6